Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session -Gastrointestinal, non-colorectal

4283 - Phase 2 trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)


19 Oct 2018


Poster Discussion session -Gastrointestinal, non-colorectal


Cytotoxic Therapy

Tumour Site

Hepatobiliary Cancers


Baek-Yeol Ryoo


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


B. Ryoo1, Z. Ren2, T. Kim3, H. Pan4, K. Rau5, H.J. Choi6, J. Park7, J.H. Kim8, C. Yen9, B. Kim10, D. Zhou11, J. Straub12, C. Zhao13, S. Qin14

Author affiliations

  • 1 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 2 Liver Cancer Institute, Department Of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai/CN
  • 3 Division Of Medical Oncology, Seoul National University Hospital, Seoul/KR
  • 4 School Of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, 310016 - Hangzhou/CN
  • 5 Division Of Hematology-oncology, Department Of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan/CN
  • 6 Department Of Internal Medicine, Yonsei University College of Medicine, 120-752 - Seoul/KR
  • 7 Center For Liver Cancer, National Cancer Center, Goyang-si/KR
  • 8 Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 463-707 - Seongnam/KR
  • 9 Department Of Internal Medicine, National Cheng Kung University Hospital, Taiwan/CN
  • 10 Department Of Internal Medicine, Kyung Hee University Hospital, Seoul/KR
  • 11 Gbem, Merck Serono Pharmaceutical R&D Co, Beijing/CN
  • 12 Global Early Development, Merck KGaA, 64293 - Darmstadt/DE
  • 13 Global Clinical Development Oncology, EMD Serono Inc, Billerica/US
  • 14 Medical Oncology Department, PLA Cancer Center, Nanjing Bayi Hospital, 210002 - Nanjing/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4283


MET is a potential therapeutic target in HCC. Tepotinib, a potent and highly selective MET inhibitor, has antitumor activity in pts with MET+ tumors. Phase 1b of the current trial (NCT01988493), confirmed the recommended phase 2 dose (RP2D) of tepotinib in Asian advanced HCC pts; here we describe phase 2 outcomes for tepotinib vs sorafenib.


Asian adults with MET + (2+ or 3+ by immunohistochemistry) advanced HCC (Barcelona clinic liver cancer Stage B/C; Child-Pugh Class A without encephalopathy; Eastern Cooperative Oncology Group performance status 0–1; no prior systemic advanced HCC therapy) were randomized (1:1) to tepotinib 500 mg once daily (RP2D) or sorafenib 400 mg twice daily in 21-day cycles. Endpoints: time to progression (TTP: primary endpoint), safety, progression-free survival (PFS), overall survival (OS) and tumor response. Efficacy was assessed by independent review committee (IRC) and investigators.


Of 90 pts randomized, 75 were included in the efficacy analysis (tepotinib n = 38, sorafenib n = 37): median age 57 [range 31–78] years; 84.0% <65 years old; 94.7% male). TTP by IRC was statistically significantly longer for tepotinib vs sorafenib (2.8 vs 1.4 months; hazard ratio [HR] (90% confidence interval [CI]): 0.42 (0.26, 0.70); p = 0.0043). Median PFS by IRC was also statistically significantly longer for tepotinib (2.8 vs 1.4 months; HR (90% CI): 0.53 (0.33, 0.84); p = 0.0229). Median OS was similar between arms (tepotinib 9.3 vs sorafenib 8.6 months; HR [90%CI] 0.73 [0.43, 1.12]; p = 0.3039). Objective response rate by IRC was 10.5% (tepotinib) vs 0% (sorafenib) (p = 0.0438). There were 4 partial responses, all in the tepotinib arm. IRC outcomes were supported by investigator read data. In the safety analysis, treatment-related treatment-emergent adverse events (TRTEAEs) occurred in 37/45 (82%) and 43/44 (98%) pts and TRTEAEs grade ≥3 in 13/45 (29%) and 20/44 (46%) pts in the tepotinib and sorafenib arms, respectively. No new safety signals were noted.


Tepotinib provided significantly longer TTP and PFS than sorafenib in Asian pts with MET+ advanced HCC, with fewer reported overall and grade ≥3 TRTEAEs.

Clinical trial identification


Legal entity responsible for the study

Merck KGaA, Darmstadt, Germany.


Merck KGaA, Darmstadt, Germany.

Editorial Acknowledgement

Medical writing assistance was provided by Helen Swainston PhD of Bioscript Science (Macclesfield, UK) and funded by Merck KGaA, Darmstadt, Germany.


J-W. Park: Honoraria: Bayer, BMS, Ono; Consulting and Advisory: BMS, Ono, Bayer, Eisai, Midatech, Roche; Corporate-sponsored research: BMS, Ono, Eisai, Bayer, Roche, Blueprint, AstraZeneca, Exelixis. D. Zhou: Employee: Merck Serono. J. Straub: Employee: Merck KGaA. C. Zhao: Employee: EMD Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.